Alvotech Reveals Positive Data For Stelara Rival

Results For AVT04 Ustekinumab Biosimilar Come Ahead Of Oaktree SPAC Merger Vote

 
• By David Wallace
$9bn nine billion dollars yellow icon
Stelara represents a $9bn target for Alvotech • Source: Shutterstock

More from Biosimilars

More from Products